VERU INC. — 10-Q Summary
Entity and period: The supplied filing is for The Female Health Company and Subsidiaries, not Veru Inc. It covers the unaudited fiscal first quarter ended December 31, 2012 (three months; filed January 30, 2013). The company’s business was the manufacture and sale of the FC2 Female Condom.
Financial performance
| Metric | Q1 FY2013 | Q1 FY2012 | Change / context |
|---|---|---|---|
| Net revenue | $9.91 million | $8.63 million | +15%; unit sales rose 13% and average selling price rose 2% |
| Gross profit / margin | $5.97 million / 60% | $5.02 million / 58% | Gross profit +19%; improved manufacturing overhead absorption cited |
| Operating income | $3.60 million | $2.78 million | +29% |
| Net income | $3.53 million | $2.66 million | +33%; net margin was 36% versus 31% |
| Diluted EPS | $0.12 | $0.09 | Comparative figures as reported |
| Operating cash flow | $1.02 million | $1.86 million | Lower despite higher net income; working-capital changes used $2.86 million |
Balance sheet and liquidity: At December 31, 2012, cash was $4.28 million, restricted cash $0.06 million, accounts receivable $7.84 million, inventory $1.82 million, and current liabilities $5.65 million. Working capital was approximately $11.1 million and stockholders’ equity was $24.5 million. Cash declined $1.02 million during the quarter, reflecting operating cash generation offset by $1.74 million in dividends and $0.18 million in treasury-stock purchases, among other items.
Debt and credit: No borrowings were outstanding. The company had a revolving credit facility of up to $2 million, subject to a borrowing base, extended through August 1, 2013 and secured by substantially all company assets. The company stated it had no significant interest-rate exposure at quarter-end.
Business developments and outlook
- Revenue and earnings grew year over year, partly reflecting higher unit volume and price. Management cautioned that quarterly results can vary materially with large-order timing, tenders, and production schedules.
- FC2 was available in 138 countries; the company reported total production capacity of approximately 100 million units annually. Expanded Malaysian manufacturing lines began operating in October 2012.
- Management believed cash was adequate to fund operations for the next 12 months, while noting there was no assurance. No specific financial forecast or earnings guidance was provided.
- Under a program announced in connection with the 2012 London Summit, the company planned to invest up to $14 million over six years in education and training, without a specific spending timetable, and to provide major purchasers with free product equal to 5% of annual units purchased beginning in fiscal 2013. The latter could affect gross margin.
- The board declared a $0.06-per-share quarterly dividend, approximately $1.7 million, payable February 6, 2013. Future dividends remain at the board’s discretion. The company also repurchased 25,000 shares during the quarter for $178,000.
Risks, contingencies, and unusual items
- The company depended on a single current product, FC2, and on public-health programs, donor funding, government procurement, and distribution partners. Tender timing and large-customer purchasing patterns can cause significant sales volatility; two South African customers represented more than 10% of quarterly revenue in aggregate.
- Other risks included competition, including the possibility of additional female-condom products qualifying for regulatory or WHO procurement; FDA and other regulatory compliance; manufacturing disruption; raw-material and foreign-currency exposure; and the ability to fund working capital and planned promotional spending.
- Product-liability coverage was $5 million. The filing disclosed no specific material litigation outcome; it stated that risk factors had not materially changed from the 2012 Form 10-K.
- Disclosure controls were assessed as effective, and the company reported no material change in internal control over financial reporting during the quarter.
Most important facts to verify
- Confirm the filing’s issuer: the supplied 10-Q identifies The Female Health Company, not Veru Inc.
- Assess the sustainability and timing of revenue growth, especially major public-sector orders and customer concentration.
- Track receivables, working-capital cash use, and the ability to maintain dividends and repurchases while funding planned education, training, and free-product commitments.
- Verify credit-facility availability and renewal, as the stated facility term ended August 1, 2013.
- Monitor gross-margin effects of production volume, free-product awards, and manufacturing or raw-material costs.